Cargando…

Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry

AIMS: Several studies and registries have demonstrated sustained reductions in blood pressure (BP) after renal denervation (RDN). The long-term safety and efficacy after RDN in real-world patients with uncontrolled hypertension, however, remains unknown. The objective of this study was to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahfoud, Felix, Böhm, Michael, Schmieder, Roland, Narkiewicz, Krzysztof, Ewen, Sebastian, Ruilope, Luis, Schlaich, Markus, Williams, Bryan, Fahy, Martin, Mancia, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837160/ https://www.ncbi.nlm.nih.gov/pubmed/30907413 http://dx.doi.org/10.1093/eurheartj/ehz118

Ejemplares similares

Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINE
por: Mahfoud, Felix, et al.
Publicado: (2023)

Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry
por: Schmieder, Roland E, et al.
Publicado: (2022)

Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry
por: Mahfoud, Felix, et al.
Publicado: (2017)

Renal denervation after the symplicity HTN-3 trial
por: Warchoł-Celińska, Ewa, et al.
Publicado: (2014)

Renal Denervation after Symplicity HTN-3: An Update
por: Persu, Alexandre, et al.
Publicado: (2014)

SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?
por: Patel, Hitesh C, et al.
Publicado: (2014)

Renal Denervation for Chronic Heart Failure: Background and Pathophysiological Rationale
por: Böhm, Michael, et al.
Publicado: (2017)

Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension
por: Fadl Elmula, Fadl Elmula M., et al.
Publicado: (2015)

Treating resistant hypertension: role of renal denervation
por: Urban, Daniel, et al.
Publicado: (2013)

Retrospective morphometric study of the suitability of renal arteries for renal denervation according to the Symplicity HTN2 trial criteria
por: Schönherr, Elisabeth, et al.
Publicado: (2016)

Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial
por: Kario, Kazuomi, et al.
Publicado: (2022)

Renal denervation in hypertensive patients not on blood pressure lowering drugs
por: De Jager, Rosa L., et al.
Publicado: (2016)

Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension
por: Mahfoud, Felix, et al.
Publicado: (2021)

Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial
por: Stoiber, Lukas, et al.
Publicado: (2018)

Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy
por: Kario, Kazuomi, et al.
Publicado: (2019)

Editorial comment: Renal denervation
por: Schmieder, Roland E., et al.
Publicado: (2021)

Renal denervation reduces left ventricular mass in patients with resistant hypertension - results from a multicenter CMR-study
por: Mahfoud, Felix, et al.
Publicado: (2013)

Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
por: Böhm, Michael, et al.
Publicado: (2020)

Correction to: Rationale and design of two randomized sham‑controlled of catheter‑based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN‑OFF MED Pivotal) and presence (SPYRAL HTN‑ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
por: Böhm, Michael, et al.
Publicado: (2020)

A drug-induced hypotensive challenge to verify catheter-based radiofrequency renal denervation in an obese hypertensive swine model
por: Lauder, Lucas, et al.
Publicado: (2020)

Histological evidence supporting the durability of successful radiofrequency renal denervation in a normotensive porcine model
por: Sharp, Andrew S.P., et al.
Publicado: (2022)

Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial
por: Weber, Thomas, et al.
Publicado: (2022)

SYMPLICITY HTN-3 results to be announced: a mystery or a story foretold?
por: Staessen, Jan A, et al.
Publicado: (2014)

Renal ablation for treatment of hypertension without Symplicity catheter: The first human experience
por: Honarvar, Mehrdad, et al.
Publicado: (2013)

Procedural and anatomical predictors of renal denervation efficacy using two radiofrequency renal denervation catheters in a porcine model
por: Wolf, Milan, et al.
Publicado: (2018)

Renal Denervation in Daily Practice: If So, How?
por: Millenaar, Dominic, et al.
Publicado: (2020)

Renal denervation in patients with chronic kidney disease: current evidence and future perspectives
por: Schmieder, Roland E
Publicado: (2022)

Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension
por: Fengler, Karl, et al.
Publicado: (2017)

Effects of Renal Denervation Documented in the Austrian National Multicentre Renal Denervation Registry
por: Zweiker, David, et al.
Publicado: (2016)

Adherence to antihypertensive medication in renal denervation trials: new studies, old problems?
por: Lauder, Lucas, et al.
Publicado: (2023)

Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update
por: Borghi, Claudio, et al.
Publicado: (2019)

Multi-organ denervation: a novel approach to combat cardiometabolic disease
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2023)

EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry
por: Gitt, Anselm K, et al.
Publicado: (2013)

Renal Denervation: A Practical Guide for Health Professionals Managing Hypertension
por: Schmieder, Roland, et al.
Publicado: (2023)

The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study
por: Schmieder, Roland E., et al.
Publicado: (2016)

Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry
por: Gitt, Anselm K., et al.
Publicado: (2016)

Renal denervation reduces atrial remodeling in hypertensive rats with metabolic syndrome
por: Selejan, Simina-Ramona, et al.
Publicado: (2022)

Sympatho-renal axis in chronic disease
por: Sobotka, Paul A., et al.
Publicado: (2011)

Executive Summary of the Joint Position Paper on Renal Denervation of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) and the European Society of Hypertension (ESH)
por: Moss, Jonathan G., et al.
Publicado: (2016)

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry
por: Bramlage, Peter, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r8e02umi9cc91bt7k44olh9r8b